Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2019.0281


New targeted drugs for Breast cancer for improving survival.

E. Ignatiadou, MD.


The breakthrough addition of pertuzumab or neratinib to established trastuzumab and chemotherapy for HER-2 positive breast cancer represent a new clinical success increasing cure rates for resectable tumors and transforming metastatic cancer disease into chronic disease. New research focuses on reducing acquired resistance. The integration of molecular classification of breast cancer according ER, PR and HER2 status into patient subgroups with crucial prognosis and treatment decision making revolutionizes cancer therapy. Combination of classical clinico-pathologic characteristics (age, histological grade, TNM stage) with molecular markers towards personalized treatment of women with breast cancer are improving relapse free and overall survival rates.

(Citation: Gastric & Breast Cancer 2019; 14(1): 28-32).

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €35 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 10 June 2019